National Announcement of FDA Approved Infusion Technology

CARSON CITY, Nev. (Business Wire EON) April 21, 2008 -- VitalCare Diabetes Treatment Centers, Inc. (NASDAQ: VDTI), a Nevada Corporation, today announced the FDA approval (called allowance to market) exists for the infusion devices used by VitalCare for its Intracellular Activation Therapy (iCAT) treatment of Type 1 and Type 2 diabetes. Jimmy McDougald, CEO stated, stated, “This is a major factor in the establishment of our treatment centers, as we begin to move iCAT into the commercial market.”

With the only FDA approved device delivering this treatment, we will expect to sign agreements to start the establishment of iCAT Treatment Centers immediately.

iCAT Therapy utilizes the special use micro-pulse insulin delivery pump with proprietary software (algorithms) incorporated into its logic. This uniquely designed pump delivers small “micro-doses” of insulin in a pattern which mimics the way a normal pancreas secretes insulin which is used by the liver. iCAT Therapy also uses “real-time” measurements of the patient’s blood sugar levels and bodywide metabolic rate by the use of a metabolic measurement cart. This data is inputted into the pump which automatically adjusts the next insulin dosage to stimulate more normal metabolism. The metabolic cart uses state-of-the-art technology to measure exhaled CO2 from the exhaled breath of the patient, and the result of our iCAT Therapy is the “reactivation” of normal metabolism in the patient. With normalization of liver enzyme functions, the body’s cells begin to utilize glucose, something that people with diabetes cannot do normally. This treatment restores the optimum metabolism bodywide which promotes healing.

By addressing the core problem of diabetes, improper metabolism (fat metabolism), iCAT Therapy is able to achieve unique stabilization of diabetes complications, and in many cases, a reversal of the secondary complications of both Type 1 and Type 2 diabetes has been clinically documented. No other technology or protocol has ever demonstrated this type or level of success.

There are over 20.8 million children and adults in the United States, approximately 7% of the US population, who have diabetes. While an estimated 14.6 million have been diagnosed with diabetes, roughly 6.2 million people (or nearly one-third) are unaware that they have the disease.

In 2007, the total estimated cost of diabetes in the United States was $174 billion in terms of direct medical expenditures and lost productivity. Diabetes is more than a major health crisis - it’s a legitimate national threat to America’s economy. Jimmy McDougald, CEO, further stated, “With the only FDA approved device delivering this treatment, we will expect to sign agreements to start the establishment of iCAT Treatment Centers immediately.”

About VitalCare Diabetes Treatment Centers, Inc.

VitalCare Diabetes Treatment Centers, Inc. is a publicly traded company specializing in providing Administrative, Marketing, Business Development, Strategic Planning, Clinical Oversight and Clinical Management Services to the Diabetes Healthcare Sector. VitalCare will become the premier company bringing “Cutting Edge” medical devices and healthcare services direct to consumers, focusing on the emerging FDA approved, US and European patented technology and treatment intervention for treating Type 1 and Type 2 diabetes known as “Intercellular Activation Therapy (iCAT).”

Safe Harbor Statement: Forward-looking statements in this release with respect to VitalCare Diabetes Treatment Centers, Incorporated’s business, financial condition and results of operations, as well as matters of timing and the prospective terms of the transaction described are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond VitalCare Diabetes Treatment Centers, Incorporated’s control with respect to market acceptance of their technology and/or products, whether financing will be available, the effect of the application of acquisition accounting policies as well as certain other risk factors which are and may be detailed from time to time in VitalCare’s filings with the Securities and Exchange Commission.

Post Comment:
Trackback URL: http://eon.businesswire.com/pingpr.php/Q3Jhcy1TaW5nLVByb2YtSW5zZS1GYWx1LVplcm8=

diabetes vitalcare treatment therapy centers infusion technology device fda_approved metabolism

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web